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The existence of a second receptor binding site on 
human prolactin (hPRL) was investigated by site- 
directed mutagenesis. First, 12 residues of helices 1 and 
3 were mutated to alanine. Since none of the resulting 
mutants exhibit reduced bioactivity in the Nb2 cell pro- 
liferation bioassay, the mutated residues do  not  appear 
to be functionally necessary. Next, small residues sur- 
rounding the helix l-helix 3 interface were replaced 
with Arg andlor Trp, the aim being to sterically hinder 
the second binding site. Several of these mutants exhibit 
only weak agonistic properties, supporting our  hypoth- 
esis that the channel between helices 1 and 3 is involved 
in a second receptor binding site. We then analyzed the 
antagonistic and self-antagonistic properties of native 
hPRL and of several hPRLs analogs altered at binding 
site 1 or 2. Even at high concentrations (-10 pd, no 
self-inhibition was observed with native hPRL; site 2 
hPRL  mutants self-antagonized while site 1 mutants did 
not. From these data, we  propose  a  model  of hPRL-PRL 
receptor interaction which slightly differs from that 
proposed earlier for the homologous  human  growth  hor- 
mone  (hGH)  (Fuh, G., Cunningham, B. C., Fukunaga,  R., 
Nagata, S., and Goeddel, D. V., and Well, J. A. (1992) 
Science 256,1677-1680).  Like hGH,  hPRL would  bind se- 
quentially to two receptor molecules, first through site 
1, then through site 2,  but  we  would expect the two sites 
of hPRL to display, unlike the two binding sites of hGH, 
about the same binding affinity, thus preventing self- 
antagonism at high concentrations. 
~~ 
Prolactin (PRL)’ is a pituitary-secreted hormone. I t  belongs 
to a protein family which also  includes  growth hormone (GH) 
and  placental lactogen (for reviews, see Miller and  Eberhardt, 
1983; Nicoll et al., 1986). PRL is involved in a wide variety of 
biological functions, mainly  related to  reproduction, lactation, 
osmoregulation, and immunomodulation (reviewed in Clarke 
and  Bern, 1980). The biological activities of PRL are  mediated 
by specific membrane receptors called lactogenic receptors 
(PRLR; Kelly et al., 1991,  1993). On the  basis of several con- 
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served features (a single transmembrane domain, conserved 
amino acid  sequences in  the  extracellular domain), the PRLR 
has been linked to the cytokine (or hematopoietic) receptor 
superfamily  (Bazan, 1989; Sprang  and  Bazan, 1993). Interest- 
ingly, the specific GH receptor (GHR, called the somatogenic 
receptor) belongs to  the  same receptor  superfamily. 
Over the  past 5 years,  there  have been several  reported  mu- 
tational  studies  aimed at elucidating  structure-function  rela- 
tionships  within  the  PRIJGH  protein family. In 1991, Chen  and 
colleagues expressed  a G119R mutant (Gly replaced with Arg) 
of bovine GH  (bGH) in transgenic mice and found it to produce 
a  dwarf  phenotype.  The reason  was unclear, at first, because 
Gly”’ is on helix 3 (Abdel-Meguid et al., 1987), and  the  binding 
site of GH had been  unambiguously linked  to a region  lying on 
another face of the  protein, delimited by portions of helix 1, 
helix 4, and loop 1 (Cunningham et al., 1989; Cunningham  and 
Wells, 1989). The explanation came from later mutational 
(Cunningham et al., 1991) and  structural  (de Vos et al., 1992) 
studies of human GH (hGH),  demonstrating  the involvement of 
a second region,  including the helix 3 glycine (Gly’?’ in hGH, 
Gly”’ in bGH) and  surrounding  amino acids, in the binding of 
hGH  to a second GHR molecule. When the helix 3 Gly is  mu- 
tated  to Arg, this  binding  site 2 is sterically  hindered  and  the 
hormone can no longer  induce  receptor  dimerization. The  fact 
that GH mutants  carrying  the Gly + Arg mutation  are biologi- 
cally inactive  and  act, moreover, as perfect hGH  antagonists led 
Fuh et al. (1992,  1993) to propose that receptor dimerization  is 
an absolute  requirement for signal transduction by the GHR. 
Formation of receptor homo- or heterodimers (or oligomers) 
has  also been reported for several  other  members of the cyto- 
kine receptor  family (Fukunaga et al., 1990; Watowich et al., 
1992; Stahl et al., 1993; for reviews, see Young, 1992; Stahl  and 
Yancopoulos, 1993). Association of membrane  proteins is thus 
anticipated for all cytokine  receptors.  PRL-induced  dimeriza- 
tion of the PRLR has neither  been proved nor disproved. How- 
ever, the observation that  bivalent,  but  not monovalent, mono- 
clonal antibodies  raised  against PRLR exhibit PRL agonistic 
properties  brought some indirect evidence that activation of the 
PRLR probably occurs upon dimerization  (Elberg et al., 1990). 
Moreover, Hooper et al. (1993) observed the formation of 1:2 
complexes between ovine PRL  and  the  extracellular domain of 
the rat PRL  receptor and  anticipated a similar stoichiometry 
for the  membrane-anchored receptor. Studies  using  the  extra- 
cellular  domain of the receptor remain controversial, however, 
since other  investigators  have  reported 1:l complexes in simi- 
lar experiments  (Gertler et al., 1993; Bignon et al., 1994). 
Another way to investigate  the occurrence of PRL-induced 
dimerization of the PRLR is to identify on the  hormone a region 
involved in  contact  with a second PRLR molecule, or in  other 
words, a second receptor binding  site. Binding site 2 of hGH 
consists of a hydrophobic channel bordered by residues of the 
N-terminal  tail, helix 1, and helix  3 (Cunningham et al., 1991; 
de Vos et al., 1992). Two residues of the GHR extracellular 
domain, T C p 1 O 4  and  TI-P’~~, play a critical role in  the  interaction 
with  hGH  binding  site 2 (Bass et al., 1991; de Vos et al., 1992). 
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FIG. 1. Helix  wheel  representation of helices 1 and 3. Curued  arrows below helix  numbers symbolize the  antiparallel  sense of rotation of 
both  a-helices. Boxed amino  acids  correspond  to  positions  which  were  mutated  to  alanine.  Arrowheads how the 4  residues which were  mutated 
to Trp (W), Arg ( R ) ,  or both (W, R).  Ar$l and TyrZ8, which  were  previously mutated (Luck  et al., 1990,1991),  are  labeled  with black points. Helices 
2 and 4  (not  shown)  are  roughly  located, respectively, below helices 3 and 1 (Abdel-Meguid et al., 1987). 
Interestingly, these  2 Trp residues are ubiquitous within the Methods 
PRL-GH receptor family  (Kelly et al., 1993) but  mutated in all 
other members of the cytokine receptor superfamily (Cosman e t  
al., 1990). Conservation of these Trp residues suggests that, 
similar to what is observed at binding site 1 (Goffin e t  al., 1992, 
19931, PRL might bind to a second PRLR by a mechanism 
similar to that described for  hGH (de Vos et al., 1992). 
To date,  there  is no three-dimensional structure available for 
any PRL. To circumvent this lack of data, we recently con- 
structed a model of hPRL,' and proposed a location for the 
putative second binding site. On the basis of helical positions 
and of their side chain conformations and orientations, we ini- 
tially selected a dozen residues potentially involved in  the in- 
teraction with a second PRLR (Fig. 1): four on helix 1 (Valz4, 
Leuz5, IleZ9, and Leu3') and eight on helix 3 (Glu"O, Ile1l2, Ser1l4, 
Lys115,  Glu'l', Gin"' , Ar g lZ5 and G1ulZ8). In a  first  step,  alanine- 
scanning site-directed mutagenesis was used to characterize 
the involvement of these 12 residues in  the biological function 
of hPRL. We monitored the bioactivity of each single mutant  in 
the widely used Nb2 cell proliferation bioassay (Gout et al., 
1980; Tanaka e t  al., 1980). The results obtained with this  first 
set of mutants led us subsequently to design a second set of 
mutations, using a different mutational strategy. 
EXPERIMENTAL PROCEDURES 
Materials 
Restriction enzymes and DNA ligase were purchased from Boeh- 
ringer Mannheim (Mannheim, Germany), Amersham International 
(Buckinghamshire,  United  Kingdom), Life Technologies Inc., and  Euro- 
gentec (Seraing, Belgium). Iodogen and bovine y-globulin were pur- 
chased  from  Sigma  and  carrier-free Na-r251 was  obtained from Amer- 
sham  International.  Ampholytes (5-7 pH  range)  and p1 protein  markers 
were from Pharmacia (Uppsala, Sweden). Site-directed mutagenesis 
was performed by the M13 procedure, using the oligonucleotide-di- 
rected  in  vitro  mutagenesis  systems of either  Amersham  International 
or  Boehringer  Mannheim.  Purification of native WRL  and hPRL  ana- 
logs was  performed by gel  filtration  chromatography  using  Sephadex 
G-100  (Pharmacia,  Uppsala,  Sweden)  packed  in a 100 x 2.6-cm column 
(Pharmacia).  Apparent  molecular  mass (MM) of PRL  analogs  were  es- 
timated by gel  filtration  chromatography  using a Superose  12  column 
(25  ml,  Pharmacia)  mounted  on a fast  protein  liquid  chromatography 
system  (Pharmacia).  Culture  media  and  sera  were  purchased from Life 
Technologies Inc. 
Oligonucleotide-directed  Mutagenesis 
All mutated  hPRL cDNAs were  constructed by the oligonucleotide- 
directed  mutagenesis  method of Sayers  et al. (1988), using  the  single- 
stranded  M13 as the vector. We used the oligonucleotide-directed mu- 
tagenesis  system of Amersham or Boehringer  Mannheim  and  strictly 
followed the manufacturer's instructions. Clones containing the ex- 
pected  mutation  were  identified by DNA sequencing,  and  the  mutated 
cDNAs were  digested  with  NdeI  (initial ATG) and Hind111 (3"noncoding 
region of the  hPRL  cDNA Cooke et al., 1981).  The  isolated cDNA frag- 
ments (660  base  pairs)  were  reinserted  into the pT7L expression vector 
(Paris  et al., 1990).  The  sequences of the  mutated oligonucleotides are 
reported below (5' + 3' noncoding strand,  mutated codon underlined). 
Alanine  substitutions  are  as follows. V24A, 5'-GTG GGA  CAG m 
GAC  GGC GCG-3'; L25A, 5"GTA TGT GGA  GAC  GAC GGC-3'; 
I29A, 5"GAG GTT ATG GTA GTG GG-3'; L32A, 5"TTC TGA GGA 
GGC GTT ATG GAT-3'; EllOA, 5"TAG GAT AGC CGC CGG GGC 
E - 3 ' ;  I112A, 5°C TTT G G A T A G m A G C  CTC CGG-3'; S114A,  5°C 
TAC AGC TTT TAG  GAT AGC-3'; K115A, 5"CTC TAC AGC TGC 
GGA  TAG  GAT-3'; E118A, 5"CTC CTC AAT CGC TAC  AGC TTT G-3'; 
Q122A, 5"CCG TTT GGT TGC CTC CTC AAT C-3'; R125A, 5"CTC 
TAG  AAG CGC TPI' GGT TTG-3'; E128A, 5"CTC  CAT  GCC CGC TAG 
AAG CCG-3'. 
The TrplArg substitutions  are  as follows. A22W, 5'-CAG GAC GAC 
GAC GGC-3' (degenerate  primer); S26W (R), 5'-GAT GTAGTG CCA(T) 
CAG  GAC  GAC-3' (degenerate  primer); G129R, 5'-CAG CTC CAT Q2'J 
CTC TAG  AAG-3'. 
Expression a n d  Purification of Proteins 
Recombinant  native  hPRL and  hPRL  analogs  were  overexpressed  in 
500-ml  cultures  ofEscherichia coli BL21(DE3)  and  purified as described 
previously  (Paris  et al., 1990). Briefly, when  the OD,,o of the  bacterial 
cultures reached 0.9, overexpression was induced with 1 mM IFTG. 
Maximal  overexpression  was  obtained by a 4-h induction (OD,, -2.5). 
Human PRL was overexpressed as insoluble inclusion bodies which 
were solubilized in  8 M urea (5 mid55 "C, then  2 Wroom temperature) 
and refolded by continued  dialysis  (72  h, 4 "C) against 20 mM NH,HCO,, 
pH  8.  Renatured  hPRL  was  concentrated  in a DIAFLO ultrafiltration 
cell with  a YMlO membrane (Amicon Co, MA) and purified on a  Seph- 
adex G-100 molecular sieve; fractions corresponding to monomeric 
hPRL  were collected and pooled. Purified  proteins  were lyophilized for 
at least  24  h  and  stored at 4 "C. 
Quantification of Proteins-Proteins  were  quantified  physically by 
weighing the lyophilized powder on a precision  balance  (Electrobalance, 
Cahn  26)  and  chemically by the Bradford  (1976)  method.  The  disparity 
between  weight  and  chemical  measurements  never xceeded 20%. 
GCG GTC AAA C-3'; L25W (R), 5"GTA TGT GGA  CCA (T) GAC 
Electrophoretic  Analyses 
V. Goffn, J. A. Martial,  and N. L. Summers,  manuscript  submitted SDS-PAGE-Protein size and  purity  were  assessed by SDS-polyac- 
for publication. rylamide gel electrophoresis (PAGE) under  reducing  conditions  (2-mer- 
 at UNIV DE LIEG
E-M
M









32600 Prolactin Second Binding  Site 
captoethanol) according to Laemmli (1970). Electrophoresis was per- 
formed for 1 h a t  150 V in vertical slab gels (Hoefer Scientific 
Instruments, CA). The gels (15% polyacrylamide) were stained with 
Coomassie Blue. 
Zsoelectrofocusin+-The isoelectric point of hPRL analogs was esti- 
mated by isoelectrofocusing. Electrophoresis was performed on vertical 
slab gels under continuous cooling; electrode solutions were 20 mM 
acetic acid and 20 mM NaOH. The gels contained polyacrylamide (5.5%), 
glycerol (lo%),  and ampholytes in  the 5-7 pH range (5.5%). Prior to 
loading the protein samples, the pH gradient was allowed to form dur- 
ing a 15-min prerun a t  200 V. One pg of each protein diluted in sample 
buffer (ampholytes 5.5%, glycerol 10%) was loaded on the gel. The run 
was performed a t  200 V and stopped when the visible band correspond- 
ing to methyl red (PI = 3.75) was focused. Gels were fixed in 20% 
trichloroacetic acid, then  in 40% ethanol, 10% acetic acid, 0.25% SDS. 
They were then washed twice in 40% ethanol, 10% acetic acid, stained 
with 0.125% Coomassie Blue, and destained in 40% ethanol, 10% acetic 
acid. Isoelectric points of the hPRL samples were estimated by compar- 
ison with the migration of PI marker proteins. 
Structural  Analyses 
Circular Dichroism-Lyophilized proteins were resuspended in 50 
m~ NH,HCO,, pH 8, a t  a concentration of 500 pg/ml. Spectra were 
recorded with a CD6 dichrograph (Instruments SA-JOBIN YVON, 
Longjumeau, France) linked to a personal computer for data recording 
and analysis (dichrograph software, Instruments SA-JOBIN YVON, 
Longjumeau, France). For each protein, five spectra recorded between 
195 and 260 nm were averaged. Measurements were performed in 
0.1-cm pathlength quartz cell. The helicity was calculated a t  222 nm 
according to Chen et ul. (1972). 
Apparent Molecular Mass-Apparent molecular mass of the six npl 
Arg hPRL mutants were measured by high pressure liquid gel filtration 
chromatography. 100-pl samples (500 pg/ml) were loaded on a Superose 
12 molecular sieve equilibrated in 20 mM Tris-HC1, pH 8,100 mM NaCl. 
Elution was performed in the same buffer a t  a constant flow rate of  0.5 
mumin, and protein elution was monitored a t  280 nm. The column was 
calibrated with several molecular mass markers: dextran blue (void 
volume), bovine serum albumin dimers (136 kDa), bovine serum albu- 
min (68 m a ) ,  ovalbumin (45 m a ) ,  carbonic anhydrase (30 m a ) ,  and 
myoglobin  (17.5 m a ) .  
Nb2 Cell Culture and in Vitro Bioassay 
The bioactivity of the hPRL analogs was estimated by their ability to 
stimulate  the growth of lactogen-dependent Nb2 lymphoma cells (Gout 
et al., 1980). The procedure used was that of Tanaka et al. (1980). Cells 
were cultured in Fisher’s medium containing 10% horse serum  and 10% 
fetal calf serum (FCS). Twenty-four h before the bioassay, cells were 
synchronized in  culture medium containing only 1% FCS. Bioassays 
were performed in FCS-free Fisher’s medium (referred to as  the “incu- 
bation medium”). 
Various amounts of hPRL samples, diluted in incubation medium, 
were added to 2.5  ml of cells (1-2 x lo6 celldml) plated in 6-well Falcon 
plates. Two to four experiments were performed in duplicate for each 
mutant. According to the mitogenic activity of the  mutants, appropriate 
hormone concentration ranges were tested. Nb2 cells were counted with 
a Coulter counter (Coulter Electronics Ltd., Harpenden Hertsforeshire, 
U.K.) after 3 days. For each hPRL analog, the EDm, i.e. the amount of 
hormone needed to achieve half-maximal cell growth, was calculated. 
The  relative bioactivity of each mutant with respect to native hPRL was 
estimated as  the ratio of the native uersus mutant ED,, values. 
Binding  Experiments 
Binding of hPRL analogs to the lactogenic receptor was studied on 
Nb2 cell homogenates in order to avoid any  uptake or degradation of 
iodinated hPRL by intact cells. Preparation of cell homogenates and 
assay conditions have been described in detail (Gofin et ul., 1992). 
Briefly, homogenates from 3 x 10, cells were incubated for 16 h a t  25 “C 
with 30,000110,000 counts/min ‘=I-hPRL in  the presence of increasing 
amounts of unlabeled native hPRL or hPRL analogs (the final reaction 
volume was 0.5 ml). The assay was terminated by addition of 0.5 ml 
ice-cold buffer (0.025 M Tris-HC1,O.Ol M MgCI,, 0.2%  bovine  y-globulin, 
pH 7.5)  followed  by centrifugation (5 min, 11,000 xg). The supernatants 
were removed carefully, and the radioactivity of the pellets was counted 
in a gamma counter (Hybritech 002011B,  Belgium). 
Each mutant was tested three times in duplicate, except for S26W, 
for which a significant displacement curve was obtained from a single 
experiment. Specific binding was calculated as  the difference between 
radioactivity bound in  the absence (Bo, maximal binding) and  in  the 
A 
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logs.A, SDS-PAGE under reducing conditions (2-ME) of production and 
FIG. 2. Electrophoretic analysis of native WRL and hPRL ana- 
successive purification stages of recombinant native hPRL. Lane l ,  
molecular mass  markers; lunes 2 and 3, 25 pl of BL2UDE3) E. coli 
culture before (OD,, = 0.9) and  after (OD, = 2.5) a 4-h induction with 
1 mM IFTG, respectively; lune 4 ,3  pg of insoluble hPRL inclusion bodies; 
lane 5.3 pg of the monomeric hPRL fraction recovered after Sephadex 
hPRL and hPRL analogs. Electrophoresis was performed at  200 V un- 
G-100 gel filtration. B, isoelectrofocusing electrophoresis of native 
der continuous cooling.  Before protein samples were loaded, a pH gra- 
dient (5-7  pH range) was allowed to form during a 15-min prerun at  the 
same voltage. One pg of each protein was loaded  on the gel.  Electro- 
phoresis was stopped when electrofocusing of the methyl red band was 
achieved (see “Experimental Procedures” for more details). Only  PRL 
analogs with an altered net charge are shown. Lanes 1-8, respectively, 
represent EllOA, EllSA, E128A, G129R, L25R, native, K115A, and 
R125A hPRLs. Lane 9 shows the PI marker proteins. 
presence (nonspecific) of 2 pg of unlabeled native hPRL. In  the different 
experiments, nonspecific binding never exceeded  20% of maximal bind- 
ing. Data  are presented as percentages of specific binding. Competition 
curves were analyzed with the LIGAND PC program (Munson and 
Rodbard, 1980). The relative binding affinity of each mutant was esti- 
mated as  the ratio of the native uersus mutant IC,, values. 
RESULTS 
Production and Purification Yields 
Overexpression of recombinant hPRL in E. coli was  achieved 
by induction with 1 m~ IPTG (4 h) (Fig. 2A, lanes 2 and 3). The 
yield of overexpressed protein was about the same for the 18 
hPRL analogs as for native hPRL (2150 mditer).  In each case, 
we were able to recover about 100 mg of insoluble inclusion 
bodiediter of culture by centrifuging the broken cells  (Fig. 2A, 
lane 4). Proteins were solubilized in 8 M urea and refolded 
during a 72-h dialysis against 20 m~ NH,HCO,, pH 8. Mutant 
S26R precipitated extensively during  this step. Upon renatur- 
ation, recombinant hPRL tends to form covalent (disulfide 
bonds) and non-covalent aggregates (Paris et al., 19901, and 
renatured hPRL was routinely purified on a Sephadex G-100 
molecular sieve to separate the monomeric  hPRL,  which eluted 
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in a single peak (Fig. 2 A ,  lane 5),  from the aggregated forms, 
recovered mainly in  the void volume of the column (not shown). 
Usually,  monomeric and multimeric peaks were of similar size 
and around 30 mg  of monomeric  hPRL was recovered per liter 
of culture. With the exception of S26RIw mutants, similar 
amounts of monomer were recovered for all hPRL analogs, 
attesting a behavior similar to that of native hPRL during 
renaturation (a similar monomer/aggregates ratio). For the 
S26R and S26W mutants, however, most of the protein ap- 
peared aggregated in the multimeric protein peak. In  the mon- 
omer peaks, we recovered  only 3 mg  (S26W) and 0.7  mg (S26R) 
from the initial 500-ml cultures. 
Isoelectric Point 
The major  isoform of purified recombinant hPRL exhibits a 
PI of 6.2 (Paris et al., 1990). Introduction or removal of charged 
residues was assumed to modify the  net charge of native hPRL, 
and indeed, removal of a negative charge or addition of a posi- 
tive charge (EllOA, E118A,  E128A,  L25R, and G129R mutants) 
enhanced the PI by almost 0.3 units. Removal of a positive 
charge (K115Aand R125Amutants)  had an opposite  effect (Fig. 
2 B ) .  These observations correlate well with theoretical PI cal- 
culations predicting values of 6.59  for native hPRL and 6.77 
and 6.42,  respectively,  for the two groups of mutants.  In some 
cases, a second isoform was detected. The presence of more 
than one  isoform has been reported for native hPRL (Paris et 
al., 1990). 
Structural Characterization of the !Op /Arg hPRL Mutants 
Small-to-large side chain mutations can generate steric hin- 
drance and lead to protein misfolding  (for a review, see Eigen- 
brot and Kossiakoff, 1992). If this occurs, the observed  modifi- 
cations of biological properties can be erroneously attributed to 
the mutated residue when in fact a global alteration of protein 
structure  is responsible. Trp/Arg mutants were therefore first 
structurally characterized. 
Circular Dichroism-Prolactins are all a-proteins; circular 
dichroism is  thus appropriate for estimating  their overall sec- 
ondary structure content (Goffin et  aZ., 1992, 1993). Five Trp/ 
Arg mutants were analyzed; the supply of S26R hPRL was 
insufficient for CD analysis. The spectra are reported in Fig. 3 
and the helical contents in Table IA. 
The analyzed mutants exhibited spectra typical of all a-pro- 
teins, with two minima, at 208 and 222 nm, and  a maximum 
around 195 nm. Spectra obtained with native, A22W, L25R, 
L25W, and G129R hPRL were almost superimposable; the 
curve obtained for the G129R mutant  is presented in Fig. 3 as 
an illustration. The helical content was calculated as described 
previously (Chen et al., 1972). For the above mentioned mu- 
tants, helicity lies in  the 50-55% range, in keeping with previ- 
ous analyses of native hPRL  (Goffin et al., 1992, 1993). 
The spectrum of the S26W mutant is slightly different in that 
the minimum at 222  nm is less pronounced than  the minimum 
at 208 nm (Fig. 3). Consequently, the calculated helicity is  a few 
percent lower (45%). 
Apparent Molecular Mass-The apparent molecular mass of 
a protein is  related to its global  folding (shape, compactness). 
Retention time on a molecular sieve was used to estimate the 
apparent molecular mass of the six “rp/Arg hPRL mutants. 
Results are reported in Table IB. None of the six mutants 
analyzed differed significantly in apparent molecular mass 
from native hPRL. 
Biological Analysis of the hPRL Mutants 
To estimate the bioactivity of the hPRL mutants, we meas- 
ured their ability to stimulate proliferation of rat lymphoma 
Nb2 cells whose growth is lactogen-dependent. As described 
- 
- 1  000 - 
200 220 240 260 
nrn 
FIG. 3. Circular  dichroism analysis of “ r p / A r g  hPRL analogs. 
Lyophilized protein samples were  resuspended at 0.5 mg/ml in 50 m~ 
NH,HCO,, pH 8. Spectra were measured in a 0.1-cm pathlength  quartz 
cell in  the shortwave UV range (195-260 nm); ordinate azis is expressed 
in M” cm”. All spectra exhibit the profile typical of all  a-proteins,  with 
two minima (208, 222 nm) and one maximum (195 nm). Spectra of 
G129R (continuous  line) and S26W (broken  line) analogs are shown. 
Spectra obtained with native, A22W, L25R, L25W, and G129R hPRLs 
were almost indistinguishable. S26W exhibited a slightly different 
curve with a less pronounced minimum a t  222 nm. Helicity contents of 
the different proteins  are reported in Table IA. 
TABLE I 
Structural  analysis of fiplArg hPRL analogs 
Fig. 3) and calculated a t  222 nm according to Chen et al. (1972). Mutant 
Part A, the helical content  was  measured by circular dichroism (see 
S26R could not be tested because of low amounts available. Part B, the 
apparent molecular mass (MM) of the  mutants was estimated by gel 
filtration on a Superose 12 column mounted on a fast protein liquid 
chromatography apparatus.  The column was  eluted  with 20 mM “is- 
HC1, pH 8, 100 m~ NaCl at a flow rate of 0.5  mumin. The column was 
calibrated with different MM markers: dextran blue (void volume), 
dimers (136 m a ) ,  bovine serum  albumin (68 kDa),  ovalbumin (45 kDa), 
carbonic anhydrase (30 kDa), and myoglobin (17.5 kDa). 100 pl (0.5 
mg/ml) of each hPRL sample were loaded on the column. Retention 
times  and  the corresponding  calculated apparent MM are presented. 
Native 
hPRL A22W L25R L25W S26R  S26W  G129R 
A. Helicity 1%) 55.8 51.6 52.2 50.9 45.0 52.5 





23.5 23.6 23.3 23.6 23.0 23.2 23.0 
previously  (Goffin et al., 1992), recombinant native hPRL 
stimulates Nb2 cells as effectively as pituitary-derived hPRL, 
with half-maximal growth around 100-200 pg hPRL/ml (ED,,). 
Results obtained with the 12 alanine-substitution mutants  are 
summarized in Fig. 4. We defined the “mitogenic  potency” of 
each mutant  as  the  ratio of the ED,,  of native hPRL to the ED,, 
of the  mutant hormone. None of the analogs was significantly 
less potent than native hPRL (mutant I29A was the  least mi- 
togenic, with a potency of 67%).  Actually, several mutations of 
residues belonging to helix 3 (Glu’lO,  Ile’l’,  Lys115, Glu’2s) 
slightly but reproductibly increased the mitogenic  potency. 
The Trp/Arg substitutions were  found to affect the biological 
properties of hPRL much more strongly. This was demon- 
strated by measuring, as above, the mitogenic  effect of each 
analog on Nb2 cells (Fig. 5 B )  and by estimating  its binding 
affinity for the Nb2 receptor (Fig. 5A). 
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FIG. 4. Mitogenic activity toward Nb2 cells of the 12 alanine 
substitution hPRL analogs. Nb2 cells were cultured as explained 
under  “Experimental Procedures.” Bioassays were performed in 2.5 ml 
of incubation medium containing 1-2 x lo5 celldml. Fifty to 100 1.11 of 
serial protein dilutions were added to each well. After 3 days, cells were 
counted in a Coulter counter. The relative mitogenic potency of each 
mutant was estimated as  the amount of native uersus mutant hPRL 
required to produce half-maximal proliferation of Nb2  cells (ED,,). Each 
mutant was tested two to four times in duplicate; average values ex- 
pressed as percentages are indicated. None of the alanine mutants 
exhibited a significantly decreased mitogenic potency. 
Binding  affinities were estimated from the  ability of each 
mutant hormone to displace lZ5I-native hPRL from the Nb2 
lactogenic  receptor. Typical displacement curves are shown in 
Fig. 5 A .  As described  previously (Goffin et al., 1992), the con- 
centration of unlabeled hPRL producing half-maximal dis- 
placement of lZ5I-hPRL (IC,,) is around 2 ng/ml (-100 PM). 
Since all the competition curves are almost parallel in the 
linear  part of the sigmoid curve, comparing IC,, values is a good 
way to  estimate  the  relative affinity of each  mutant for the 
lactogenic receptor. Averaged over three different experiments, 
the IC,, ratio  (native  value uersus mutant  value)  was 16.5 2 3% 
for L25W and 17.9 2 0.14% for L25R, while the  other  analogs 
exhibited much lower affinity: 0.33 2 0.11% (A22W), 0.75 2 
0.08% (S26R), and 1.07 & 0.03% (G129R). Tested in a single 
experiment because of the  limited supply, the  measured IC,, of 
mutant S26W was 4853 ng/ml, so its affinity  for the receptor is 
about 0.03% of the affinity of native hPRL. 
The mitogenic activity of the Trp/Arg analogs was also 
strongly altered. Mutations L25R and L25W led to a 2-fold 
reduction. Averaged over three  independent  experiments,  the 
mitogenic  potencies of the four remaining  mutants were  2 to 3 
orders of magnitude lower than for native hPRL: 0.217 2 0.11% 
(A22W), 1.7 2 1% (S26R), 0.058 2 0.04% (S26W), and 0.47 2 
0.2% (G129R). 
To investigate  the  antagonistic  properties of the Trp/Arg mu- 
tant hormones, we measured their ability to inhibit native 
hPRL-stimulated Nb2 cell growth. These competition experi- 
ments were made difficult by the  intrinsic  growth-stimulating 
effect of each  mutant.  At  concentrations of native  hPRL pro- 
ducing maximal cell growth  (about 1 ng/ml),  no inhibition of cell 
proliferation by the  mutant  proteins  was observed. At low con- 
centration of native  hPRL, however, a slight  inhibition  was de- 
tected  (Fig. 6A). In  the  experiment shown, 45 2 2% (n = 4) of 
maximal cell growth  was achieved a t  0.05 ng/ml of native hPRL. 
Under  these  experimental conditions, A22W and S26W analogs 
present a t  concentrations  ranging from 0.1 to 5 ng/ml caused cell 
proliferation to decrease by about 10%. Inhibition  was  never 
more acute.  At  analog  concentrations exceeding 10 ng/ml, mu- 
tant-induced cell proliferation occurred. The  slightly  higher in- 
trinsic  activity of the G129R mutant  (see above) can be linked 
A 
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FIG. 5. Biological  analysis of the Trp/Arg hPRL analogs. A, com- 
petition curves for the displacement of ‘261-labeled native hPRL by 
unlabeled native hormone and Trp/Arg hPRL analogs. In  this experi- 
ment, Nb2  cell homogenates prepared from 3 x 10‘ cells were incubated 
with 32,000 countshin of  ‘251-labeled native hPRL (tracer) and  serial 
dilutions of unlabeled native hPRL or hPRL analogs (competitor). Spe- 
cific binding is  the difference between the radioactivity bound in the 
absence (E,) and in the presence (nonspecific) of 2 pg of unlabeled 
hPRL. In  this experiment, nonspecific binding was 17% of Bo. All curves 
presented in  this figure are  taken from the same experiment and pre- 
sented as percentages of specific binding. Each point is the average of 
duplicate measurements; maximal disparity between duplicate values 
is 12% of specific binding. The dotted curve corresponds to the G129R 
analog. B,  Nb2  cell proliferation in  the presence of Trp/Arg hPRL ana- 
logs. Bioassay conditions are described under “Experimental Proce- 
dures.” Each mutant was tested in  at  least  three different experiments. 
Each point is  the average of duplicate measurements. Disparity be- 
tween duplicate values did not exceed 15%. Argmp substitutions of 
Alazz, S e P ,  and GIY’~’ produced drastically decreased mitogenic po- 
LeuZ5 decreased the mitogenic potency by 2-fold. Point mutations at  
tency by 2 to 3 orders of magnitude (see “Results” for accurate values). 
with  the  fact that it  causes no real  inhibition  and  that it induces 
more rapid cell growth (Fig. 6A). As expected, mutants L25R 
and L25W did not compete at all  with  native  hPRL  (data  not 
shown); mutant S26R was  not  tested  due  to  the  limited supply. 
Besides studying  the  antagonistic  properties of the Trp/Arg 
mutants, observable only at low protein concentrations ( 4 0  
ng/ml), we also investigated  their self-antagonistic effects. Self- 
antagonism  is  indicated by the occurrence of bell-shaped  curves 
at extremely high protein concentrations (Fuh et al., 1992, 
1993). Protein  concentrations  up  to 250 pg/ml (-10 pd were 
used; solubility  problems prevented our testing  higher concen- 
trations.  The  results  are  presented  in Fig. 6B. We repeatedly 
observed  no  self-inhibition with  native hPRL. Mutants R125A 
and L25R likewise failed to self-antagonize. Mutants G129R 
(Fig. 6B)  and A22W (not shown),  on the  other  hand, exhibited 
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hPRL and hPRL analogs in the Nb2 cell  proliferation bioassay. 
FIG. 6. Antagonistic and self-antagonistic effects of native 
A, competition between native hPRL and Arm analogs. Three Arg/ 
Trp analogs (A22W,  S26W, and G129R)  were tested for their ability to 
antagonize native hPRL in the Nb2 cell proliferation bioassay.  Prolif- 
eration in presence of native hPRL is shown as control. The curves 
presented are averages of duplicate measurements; maximum disparity 
between duplicate values was 4% of the maximum  effect. In  this ex- 
periment, 0.05  ng/ml of native hPRL  produced 45 2 2% ( n  = 4) maximum 
cell proliferation. In  the presence of low concentrations of competitor 
(0.1-5  nglml),  cell proliferation decreased to 31-38% with S26W and to 
2940% with A22W, it remained virtually unchanged with G129R.  At 
higher concentrations, the intrinsic relative activity of each mutant 
(G129R 7 A22W > S26W, see Fig. 5E) additively increased cell  division. 
B, self-antagonistic effect at very high concentrations. The occurrence of 
bell-shaped curves in  the Nb2  cell proliferation bioassay at very  high 
hormone concentrations (about 250  pg/ml) was indicative of self-antag- 
onism. Native hPRL and both site 1 and  site  2 analogs were tested. The 
curves presented are averages of duplicate measurements; maximum 
With native hPRL, no self-inhibition was observed,  even at 250 pg/ml. 
disparity between duplicate values was 15% of the maximum effect. 
The L25R and R125A mutants (not shown), whose site 2 is altered 
weakly or not at all, did not self-antagonize either. Mutants G219R 
whose site 2 is markedly weakened, exhibited self-inhibition in the 
50-250  pg/ml range. Analog  A22W behaved similarly (not shown). Mu- 
tants K181A (not shown) and KlSlE, whose site  2  is  intact  but whose 
site 1 is weakened: failed to exhibit a bell-shaped curve. 
a bell-shaped curve  with detectable  self-inhibition in  the 50- 
250 pg/ml range. By extrapolating  the self-inhibition  curves in 
several  independent  experiments, we were  able to  determine 
IC,, values for self-inhibition ("self-IC,,"). The  values obtained 
were: 252, 256, and 570 pg/ml for G129R, and 680 and 630 
pg/ml for A22W. Finally, we tested K181A and K181E hPRL, 
two mutants whose binding  site 1 is  dramatically ~ e a k e n e d . ~  
Neither exhibited  self-inhibition at the concentrations tested. 
V. Goffin and G. Guillaume, unpublished results. 
DISCUSSION 
Alanine Substitutions-To date, no NMR or x-ray structure 
is available for any PRL. To provide an  atomic structure on 
which to base  our  mutational  studies, we recently  constructed 
a theoretical three-dimensional model of hPRL2 derived from 
the x-ray  coordinates of porcine GH, the  first elucidated 
PRIJGH protein structure (Abdel Meguid et al., 1987). This 
model enabled us  to select 12  residues  assumed  to  surround  the 
putative  binding  site 2 of hPRL. Residues Ar8' and w8, also 
presumed to be involved in  this  site,  have  already been studied 
by others (Luck et al., 1990, 1991) and were not reconsidered. 
The  alanine-scanning  approach, previously used successfully to 
identify certain  residues involved in  the biological properties of 
hGH (Cunningham et al., 1989, 19911, hPRL (Gofin et al., 
1992), or hGHR (Bass et al., 1991), was applied to  the dozen 
residues selected on the  basis of our model (see Fig. 1). Unex- 
pectedly (and excepting I29A and L32A mutations whose ef- 
fects  were  very slight), none of the  alanine  substitutions dimin- 
ished the mitogenic effect of the hPRL analogs on the Nb2 
lymphoma cell line (Fig. 4). This means  that none of the 12 
residues  initially selected on the  basis of the hPRL model is 
essential  to  the hormone's bioactivity. As shown on Fig. 1,  our 
study includes nearly  the  entire xposed, mutually facing  sides 
of helices 1 and 3, covering some two (helix 1, amino acids 
24-32) or five (helix 3, amino  acids 110-128) helix turns. There- 
fore, systematic misprediction of residues presumably involved 
in  the second binding site  seems very unlikely. Moreover, the 
proposed location for hPRL-binding site 2 is in good agreement 
with  the observed decrease of bioactivity of bPRL when Ar$' or 
T y P  are  mutated or Argi2, deleted (Luck et al., 1990, 1991). 
Studies performed on the  binding  site 1 of hGH have revealed 
that polypeptide regions can remain virtually insensitive to 
alanine  substitution  (Cunningham  and Wells, 1989; Cunning- 
ham  et al., 1989) although  their involvement at the hormone- 
receptor interface is demonstrated by structural  (de Vos et al., 
1992) or energetic (Cunningham and Wells, 1993) analysis. 
Thus, while interactions predicted by alanine  substitution do 
occur, some residue contacts can be missed by this  mutational 
approach. This could account for the lack of effect in  the  present 
study. 
Some helix 3 mutants displayed  weak, but reproducible, in- 
creased bioactivity (Fig. 4). Replacement of exposed residues 
within a-helices by alanine  tends to  stabilize  a protein (for a 
review, see  Fontana, 1991). In  the  present case,  increased sta- 
bility might explain the slightly enhanced activity. Alterna- 
tively, Ala substitution of large, hydrophilic residues (Glu"', 
Lys115, G1ulZ8) might favor the  interaction with the  large, hy- 
drophobic Trp residues of the receptor. These  hypotheses and 
others deserve further  analysis. 
Dyptophan /Arginine Substitutions-Alanine scanning  hav- 
ing proved unsuccessful for our purpose, we turned  to  the op- 
posite strategy, i.e. mutating some residues  to much larger ones 
(Trp  or Arg). The aim was to fill the helix 1-helix 3 cavity 
assumed  to form binding site 2 of hPRL. Four amino  acids were 
selected for their proximity to  the helix-helix interface and for 
the size of their side chains: Alazz, Leu2,, S e 9 ,  and GlyiZ9 
(Fig. 1). 
Of the four  selected residues,  Serz6 is the most  buried  (Fig. 1). 
Extensive aggregation and precipitation of S26W/R analogs 
upon renaturation  step probably reflects an effect of the  muta- 
tions on protein folding. Expectedly, introducing a charge (Arg) 
near the hydrophobic core was more detrimental to  folding 
than the steric effect alone (Trp). Although we detected no 
modification of the  apparent molecular mass for these  mutants 
(Table I),  their  structure  is likely to  be affected locally around 
the  Serz6  mutations. None of the four remaining Trp/Arg mu- 
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tants (A22W, L25R, L25W, G129R) appeared to be misfolded, 
since the  renaturation yield, the CD analysis,  and  the  apparent 
molecular mass were practically unchanged (Table I). Any ef- 
fects on bioactivity observed with  these  mutants  can  thus  be 
attributed to effects of the  mutations  on  the local environment 
rather  than to  a major alteration of protein  structure. 
Mutations A22W and G129R reduced both  the  binding  affh- 
ity  and  the Nb2 bioactivity by 2 to 3 orders of magnitude.  This 
result  strengthens  our  starting hypothesis concerning the crit- 
ical functional  role of the hydrophobic channel between helices 
1 and 3 (Fig. 1). Mutations at position 26 caused similar (S26R) 
or even worse (S26W) alterations of biological properties. As 
mentioned above, these  data  must be considered with  caution 
since structural effects might  be involved. Although S26R ap- 
pears to be more strongly affected structurally (see above), 
S26W hPRL  is 30-fold less  active (binding  and bioactivity; Fig. 
5);  this  suggests  that  the effect of the  latter  mutation  is  due, at 
least  in  part,  to  the  steric  hindrance produced by the Trp sub- 
stitution.  Mutating Leu25 reduced bioactivity and  binding by 
only 2- and 5-fold, respectively. As Leuz5 borders on the  central 
channel and is oriented toward  the solvent; replacement of 
this  residue by either Trp or Arg is more liable to  interfere  with 
receptor docking than  to fill the  central  channel  and  thereby 
block binding  site 2. Moreover, leucine is a medium-sized res- 
idue,  and  the  steric effect of the  mutations, especially to Arg, 
should be considerably less  marked  than when smaller resi- 
dues  are replaced (Ala, Ser, Gly). 
The positions of the residues selected for the Trp/Arg muta- 
tional  study  are incompatible with  an involvement in  binding 
site  1, delimited by the opposite face of helix 1, helix 4, and loop 
1 (Goffm et al., 1992, 1993). Our  results  thus  strengthen  the 
hypothesis that  the region delimited by the  mutually facing 
sides of helices 1 and 3 has  an  important functional role. They 
thereby provide some experimental evidence as  to  the existence 
and location of a second binding  site on hPRL. Residues  directly 
involved in contacts with  the receptor are probably not limited 
to  those which were mutated, since the  steric  hindrance  result- 
ing from small-to-large side chain substitutions can prevent 
other  surrounding amino  acids  from interacting  with  the re- 
ceptor as they do in  the  native hormone. However, since alanine 
scanning failed to point out  any  binding residue, exhaustive 
identification of the amino acids involved in the interaction 
with the receptor awaits determination of the three-dimen- 
sional structure of the PRL.PRLR complex. 
Model of PRL-PRLR Interaction-From the behavior of the 
G120R analogue, a full hGH  antagonist,  Fuh  and colleagues 
(1992, 1993) proposed a sequential dimerization model: hGH 
would first bind to one receptor through  binding  site 1 to form 
an  intermediate, inactive 1:l complex. Then  the receptor-bound 
hGH would interact with a second receptor through  binding 
site 2 to produce the active 1:2 complex (Fig. 7A). Occurrence of 
sequential dimerization can be indirectly  visualized in a dose- 
dependent cell growth bioassay (Fuh  et al., 1992, 1993). At low 
hGH  concentrations ( 4  nM), 1:2 complexes are progressively 
formed and  the growth-promoting effect is observed. At high 
hGH  concentrations (>lo0 nM), excess hormone progressively 
disrupts  the 1:2 complexes in favor of inactive 1:l complexes, 
and cell growth is progressively inhibited. Such proliferation 
curves, referred  to  as ‘%ell-shaped” curves (Fuh  et al., 19921, 
thus  constitute  experimental evidence of GH self-antagonism 
linked  with  sequential dimerization of its receptor. Given the 
similarity between hGH  and  hPRL, we expected hPRL to be- 
have  like hGH in  the hGH-GHR interaction  and  thus also to 
exhibit a bell-shaped  curve in  the Nb2 cell proliferation bioas- 
say. Testing  concentrations up to  250 pg/ml (about 10 PM), we 
failed to  detect  any significant  self-inhibition at high concen- 
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FIG. 7. Models of hormone-receptor  interaction:  comparison f 
hPRL and hGH. The upper panel represents the model recently pro- 
posed  for the interaction of hGH with the somatogenic receptor (Fuh et 
al., 1992); the interaction between hGH and the lactogenic receptor 
(Nb2) is assumed to be similar (Fuh et al., 1993). The lower panel 
lactogenic receptor (Nb2). In both cases, an inactive intermediate hor- 
represents the model  we propose for the interaction of hPRL  with the 
mane (H),-receptor(R), complex is formed first, always via receptor 
binding to site 1 of the hormones. At low hormone concentration, an 
active  HI.$  complex is formed. The behavior of hPRL and hGH  differs 
at high hormone concentration. For  hGH (upper panel), since the affin- 
ity of binding site  2  is much  lower than  that of binding site  1, excess of 
hormone binds preferentially through its binding site 1, and active 
HI.$ complexes are progressively disrupted in favor of inactive H,.R, 
complexes; this model accounts for the self-antagonism of hGH in both 
lactogenic and somatogenic bioassays (Fuh et al., 1992, 1993). In the 
case of hPRL  (lower panel), we  propose that the affinity of both binding 
ously formed  H,.R, but remains free in solution. This model accounts for 
sites  is similar. Therefore, excess of hormone cannot disrupt  the previ- 
the absence of self-inhibition at high native PRL concentrations (Fig. 
6B) .  The A22W and G129R mutants, whose binding site  2  is markedly 
weakened, behave like hGH and self-antagonize at high concentrations. 
 at UNIV DE LIEG
E-M
M









Prolactin Second Binding  Site 32605 
tration. We thus  tried  to  elucidate  the  disparity between the 
behaviors of hPRL  and hGH. 
Self-antagonism of hGH  results  not only from the existence 
of two binding  sites  but also  from differences in  their proper- 
ties: site 1 displays a large  surface  and a high affinity, site 2 a 
smaller  surface  and lower affinity (Cunningham et al., 1991; de 
Vos et al., 1992). At high hGH concentrations, consequently, 
competition for receptor binding between site 1 (on the free 
hormone) and site 2 (on the intermediate hormone-receptor 
complex) is in favor of the former (Fuh et al.,  1992). When 
excess hGH is  added  to preformed 1:2 complexes, moreover, the 
equilibrium is displaced toward formation of 1:l complexes. 
This  indicates  that 1:2 complex formation is reversible 
(Cunningham et al., 1991). In  sequential  binding of hGH,  the 
molarity at which self-inhibition occurs (formation of 1:l com- 
plexes from 1:2 complexes) seems  to  correlate with the relative 
affinities of the two binding  sites. As an  illustration,  the EC,, 
for cell proliferation and  the IC, for self-antagonism of native 
hGH are  separated by lo5 log units;  this  range drops to 3 x lo3 
log units  in a triple  mutant (H21AIR64WE174A) exhibiting a 
30-fold increased affinity at binding  site 1 (Fuh et al., 1992). 
Conversely, a mutant whose affinity at binding site 1 is de- 
creased by 560-fold (K172M176A) exhibited no detectable 
self-inhibition at   the concentration tested  (Fuh et al., 1992). In 
other words, the  higher  the difference in affinity  between  both 
binding  sites,  the  smaller  the concentration range  separating 
agonistic from self-antagonistic effects. 
Linking  these observations on hGH  mutants  with  the  ab- 
sence of any detectable self-antagonism of native  hPRL, we 
propose a model of hPRL-PRLR interaction which differs from 
the  hGH model in  that  binding sites 1 and 2 would have sim- 
ilar, if not identical, receptor binding affinities (Fig. 7B). In 
such a model, the 1:2 complexes should be much  more stable 
than  the 1:l complexes because they  result from two high af- 
finity binding events. Excess hPRL should therefore neither 
lead  preferentially to  the formation of 1:l complexes through 
binding  site 1 nor reverse preformed 1:2 complexes in favor of 
less  stable 1:l complexes. 
Since the difference between the hGH and hPRL models is 
based on the  relative affinities of their two binding sites, we 
challenged our theory by analyzing several available hPRL 
mutants at very high concentration (Fig. 6B). As expected, 
mutants whose site 2 was unaffected (R125A) or weakly af- 
fected (L25R) behaved like  native hPRL and did not self-an- 
tagonize. Conversely, mutant hPRLs with a markedly weak- 
ened binding  site 2 (G129R and A22W) exhibited  self-inhibition 
as does hGH (Fig. 7A). I t  was also important to see whether 
sequential binding occurs preferentially through one of the 
binding  sites. We therefore  tested  mutants K181A and K181E 
whose binding  site 1 is weakened by 2 and 3 orders of magni- 
tude, respectively3Although this reduction in affinity is similar 
to  that of binding  site 2 in A22W and G129R, none of these  site 
1 mutants exhibited  self-inhibition at the concentration tested. 
This strongly suggests  that  sequential binding does occur first 
via site 1. When available, other  site 1 analogs should be used 
to confirm these observations. 
Our model can  also account for the  results of the competition 
experiments performed with  the Trp/Arg mutants. When na- 
tive hPRL is present at a  concentration  producing  maximum 
cell growth  (we tested  the 1-10 ng/ml range,  data  not shown), 
almost all  the receptors (R)  are occupied in H1.Rz complexes 
with  the wild-type  hormone (HI. Added at low concentrations, 
mutants with a weakened site 2  cannot  displace these  stabi- 
lized complexes and  are ineffective. Added in excess, however, 
such mutants exhibit intrinsic mitogenic activity which adds  to 
that of the native hPRL. When the concentration of native 
hPRL is lower (0.05 ng/ml; Fig. 6A), many receptors remain 
unoccupied by the hormone. The  mutants should bind to the 
free receptors and mainly form H,.R, complexes since the 
weakened  affinity of binding  site 2  markedly  reduces the oc- 
currence of H1.Rz complexes. The receptors thus  remain 
blocked in  an almost inactive state.  That no more than 10% 
inhibition of cell proliferation could be achieved in competition 
experiments even  with a 100-fold excess (5 ng/ml) of mutant 
might  reflect the analogs' inability to displace preformed 1:2 
complexes between the receptor and  native hPRL. At higher 
concentrations, the analogs exhibit their intrinsic mitogenic 
activity; their effects and  those of native  hPRL  are additive. 
Full understanding of the competition studies will require, 
however, further  analysis. 
Finally, our model of the hPRL-PRLR interaction can ac- 
count for the  failure of the  alanine-scanning study. Due to  the 
high binding affinity of the hPRL-binding site 2, alanine sub- 
stitutions alone, conversely to  mutations which markedly  alter 
the affinity of binding site 2 (A22W, G129R), might be insuffi- 
cient to reduce cell proliferation. In hGH, the single G120R 
mutation completely blocks binding site 2, while in hPRL, 
G129R, and A22W mutations give rise to  weak  agonists. This 
also might reflect the  higher affinity of binding site 2 in hPRL. 
Conclusion-Our study  demonstrates  that  the region delim- 
ited by the  interface between helices 1 and 3 is crucial to  hPRL 
bioactivity. Alanine scanning  was  inappropriate for identifylng 
some functionally important residues. The Trp/Arg mutant 
data suggest, indeed, that at least some of the 12 residues 
selected for alanine  substitution could be involved in contacts 
with  the receptor. The model we propose for the PRL-PRLR 
interaction differs from the  earlier hGH-hGHR model in  that a 
similar affinity is predicted for both binding  sites.  Our  data 
highlight the  steric importance of small  residues  such as Alaz2 
or Gly"' in  maintaining  the geometry of binding site 2. We 
would expect PRLs from other species, possessing more cum- 
bersome residues at  these and/or other positions (in rodent 
PRL, for example, position 22 is occupied by a  valine  residue), 
to  behave differently at high  concentration. 
Our results do not tally with some of the  studies performed 
with  the soluble extracellular domain of the PRLR, predicting 
an H,:R, stoichiometry (Gertler et al., 1993; Bignon et al., 
1994). As stated by the  authors, however, the (inlability of the 
extracellular domain to form 1:2 complexes does not necessar- 
ily reflect the biological activity of the hormones tested (Bignon 
et al., 1994). Dimerization of membrane-anchored receptors 
might be markedly facilitated by additional interactions involv- 
ing  the  transmembrane and/or cytoplasmic regions of the  re- 
ceptor. This would obviously weaken interactions between the 
two molecules in the presence of the extracellular domain 
alone. This work calls for further  study:  the  antagonistic prop- 
erties of the available analogs should be  better characterized, 
new mutants should be designed, and,  as  usually formulated, 
the three-dimensional structure of receptor-bound hPRL 
should be determined. 
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